Medical patients with a history of alcohol and drug abuse require mechanical ventilation more frequently and have longer duration of mechanical ventilation and longer intensive care unit (ICU) length of stay. 7, 8 In a small, retrospective study, mechanically ventilated medical ICU patients with a history of alcohol and drug use disorders required 5-fold greater opioid equivalents and 2.5-fold greater benzodiazepine equivalents to achieve target sedation levels similar to patients without drug use disorders. 9 The existing literature in both the medical and trauma populations has primarily focused on the consequences of alcohol use disorders, both acute intoxication and chronic use, BACKGROUND: The purpose of this study was to determine whether mechanically ventilated trauma patients with a positive urine drug screen (UDS) for cocaine and/or amphetamines have different opioid analgesic and sedative requirements compared with similar patients with a negative drug screen for these stimulants. METHODS: This retrospective, single-center cohort study at a tertiary care, academic medical and level 1 trauma center in the United States included patients ≥16 years of age who were admitted to an adult intensive care unit with a diagnosis of trauma between 2009 and 2013 with a UDS documented within 24 hours of admission, and were mechanically ventilated for >24 hours. The primary end point was the daily dose of opioid received during mechanical ventilation, expressed as morphine equivalents, for patients presenting with a positive UDS for cocaine and/ or amphetamines compared with patients with a negative UDS for these stimulants. Secondary end points included the daily benzodiazepine dose and median infusion rates of propofol and dexmedetomidine received during mechanical ventilation, duration of mechanical ventilation, intensive care unit and hospital length of stay, and in-hospital mortality. Analgesic and sedative goals were similar for the duration of the study period, and both intermittent and continuous infusions of opioids and sedatives were administered to achieve these targets, although a standardized approach was not used. A multivariate logistic regression analysis and a propensity-adjusted model evaluated patient characteristics predictive of a higher median opioid requirement. RESULTS: A total of 150 patients were included in the final analysis. In a univariate analysis, opioid and sedative requirements were similar for patients presenting with a positive UDS for cocaine and/or amphetamines compared with patients with a negative UDS for these stimulants. In the multivariate regression analysis, increasing age and Abbreviated Injury Scale (head and neck) were associated with decreased daily opioid requirements (odds ratio [OR] , .95, 95% confidence interval [CI], .93-.97 and OR, .71, 95% CI, .65-.77, respectively), whereas preinjury stimulant use was not predictive of opioid requirements (OR, .88, 95% CI, .40-1.90). In a propensity score--adjusted model, preinjury stimulant use was similarly not predictive of opioid requirements during mechanical ventilation (OR, .97, 95% CI, .44-2.11). CONCLUSIONS: For trauma patients presenting with acute, preinjury use of cocaine and/or amphetamines, analgesic and sedative requirements are variables and may not be greater than those patients presenting with a stimulant-negative UDS to achieve desirable pain control and depth of sedation, although this observation should be interpreted cautiously in light of the wide CI observed in the propensity score--adjusted model. Although unexpected, these findings indicate that empirically increasing analgesic and sedative doses based on positive UDS results for these stimulants may not be necessary. (Anesth Analg 2017; 124:782-8) Analgesia and Sedation Requirements in Mechanically Ventilated Trauma Patients With Acute, Preinjury Use of Cocaine and/or Amphetamines and cointoxication with alcohol and other illicit substances. Studies directly examining the preinjury use of stimulants, such as cocaine and amphetamines, and postinjury analgesia and sedation requirements in the trauma population are lacking. According to the Substance Abuse and Mental Health Services Administration, the prevalence of cocaine use in adolescents and adults declined modestly between 2007 and 2012. 10 However, both prescription and nonmedical use of amphetamines is rising in adolescents and adults, particularly among college students. [11] [12] [13] [14] [15] In addition, driving under the influence of illicit drugs is increasing and is most prevalent among young adults 18 to 25 years of age, 10 highlighting a significant public health problem and the need for targeted therapies for these patients when traumatically injured.
The purpose of this study is to determine whether the analgesic and sedative requirements of mechanically ventilated trauma patients who have a urine drug screen (UDS) positive for cocaine and/or amphetamines are different from those who do not use these stimulants.
METHODS
The study protocol was reviewed and approved by the institutional review board at Duke University Hospital with a waiver of informed consent. This retrospective cohort study identified patients from the Duke University Hospital Trauma Registry admitted between January 1, 2009, and June 15, 2013. Inclusion criteria were ≥16 years of age, an admitting diagnosis of trauma, admission to an adult ICU, a UDS documented within 24 hours of admission, and the need for mechanical ventilation for ≥24 hours. Trauma patients ≥16 years of age were included in this study because 16-and 17-year-old trauma patients are admitted and treated in an adult ICU at our institution. Patients were excluded if they were pregnant, received targeted temperature management, received continuous neuromuscular blockade, or did not receive any opioid analgesic or sedative because of declaration of brain death or withdrawal of care. Patients with long-acting opioids documented as a home medication were also excluded because they are expected to require higher analgesic doses due to tolerance and would confound the primary outcome. Long-acting opioids included fentanyl transdermal patch, hydromorphone extended release, methadone, morphine extended release, oxycodone extended release, and oxymorphone extended release.
Institutional policy mandates that a UDS is obtained for all level 1 and level 2 trauma patients and is optional for level 3 trauma admissions. For the purposes of this study, stimulant use was defined as having a positive UDS for cocaine and/or amphetamines. All patients with a UDS positive for stimulants, regardless of other positive results and who met the study criteria, were included in the stimulant-positive arm. The stimulant-negative group consisted of anyone meeting study eligibility who did not have a positive result for a stimulant, regardless of positive results for other agents. Because a larger sample of stimulant-negative patients was available in the registry, patients were organized chronologically by admission date, and every fifth patient was evaluated for enrollment eligibility to provide an even distribution of patients admitted during the study period.
The primary end point was the median daily dose of opioid analgesia required during mechanical ventilation, expressed in morphine equivalents. Secondary end points were: the median daily dose and infusion rate of propofol; the median daily dose and infusion rate of dexmedetomidine; the median benzodiazepine daily dose, expressed in lorazepam equivalents; duration of mechanical ventilation; ICU length of stay; hospital length of stay; and in-hospital mortality. Duration of mechanical ventilation was defined as the duration of endotracheal intubation until first extubation or tracheostomy. This end point was truncated at time of tracheostomy because sedative duration may be reduced for patients after the removal of the endotracheal tube and placement of the tracheostomy. 16 During the study period, both pain and depth of sedation were assessed every 4 hours or within 30 to 60 minutes after intervention. The Numeric Rating Scale was used for those patients who could self-report pain. For patients unable to self-report pain, Face, Legs, Activity, Cry, Consolability 17 and Wong-Baker Faces or Pain Assessment in Advanced Dementia 18 were used at different points during the study period. Depth of sedation was evaluated using the Richmond Agitation Sedation Scale (RASS).
During the study period, a formal sedation protocol was not in place. Analgesic end points were defined by nursing policy (goal Numeric Rating Scale <4). Initial analgesic orders were placed at the discretion of the provider, and opioid infusions were initiated and titrated by provider order only based on pain assessment and intermittent opioid administration pursuant to nursing policy. Fentanyl and hydromorphone were the most commonly used IV opioids. RASS goal was specified in the administration instructions within the individual order for propofol and dexmedetomidine (default RASS goal −2) and titrated by bedside nurses. Benzodiazepine infusions were initiated and titrated by provider order only in response to RASS assessment and intermittent benzodiazepine use. The surgical ICU is a semi-enclosed unit staffed by: an attending physician (anesthesiology intensivist or trauma surgeon, 24 hour per day coverage); anesthesiology and/or surgical critical care fellows; anesthesiology and/or general surgery residents; advanced practice providers; and allied health staff, including a pharmacist, dietitian, respiratory therapist(s), and physical therapist(s). Multidisciplinary rounds occurwww.anesthesia-analgesia.org
ANESTHESIA & ANALGESIA
A multivariate logistic regression with backward variable selection (P < .4) was used to predict increased opioid requirements, defined as greater than the median of 1.24 mg/kg/day. Variables evaluated in the regression analysis were: age; gender; Injury Severity Score; mechanism of injury (gunshot wound), a UDS positive for stimulants, a UDS positive for cannabinoids, and a positive blood alcohol level; Glasgow Coma Scale score; Abbreviated Injury Scale (AIS; head and neck) score; AIS (spine) score; and traumatic brain injury (TBI). In addition, a propensity score--adjusted model (adjusted for all of the above variables) was used to determine the significance of a UDS positive for stimulants on opioid requirements, expressed as morphine equivalents greater than the median of the cohort. First, a logistic regression was used to obtain probability predicted scores (propensity) of the above variables to predict a UDS positive for stimulants. In a separate logistic regression, a propensity score-adjusted model in which the propensity score was used as a covariate to examine whether a UDS positive for stimulants predicted opioid requirements equivalent to or greater than the median of the cohort. Model assumptions were examined, and goodness of fit was determined. Full details of the statistical model are available in the Supplemental Digital Content (http://links.lww.com/AA/ B580). All analyses were conducted using JMP version 11 and SAS 9.4 (SAS Corporation, Cary, NC).
RESULTS
This study enrolled 150 patients: 49 with a UDS positive for cocaine and/or amphetamines, and 101 with a UDS negative for these substances (Figure) . Enrolled patients were equally distributed in each group over time, thus they were subjected to similar sedation strategies. Baseline characteristics are reported in Table 1 . In the stimulant-positive group, 10 patients (20.4%) were positive for amphetamines, 39 patients (79.6%) were positive for cocaine, and 2 patients (4.1%) were positive for both substances on the UDS. Of note, 2 of the 10 amphetamine-positive patients (20%) had amphetamine/dextroamphetamine documented as a home medication: one was admitted because of a fall after an overdose of opioids and benzodiazepines, and the second after a motor vehicle collision that involved alcohol intoxication. The nature of stimulant use was evaluated by provider review and social work progress notes documenting patient-and family-reported preinjury use. Binge use was noted in 7 patients (14.2%), chronic ingestion for 23 patients (46.9%), and 19 patients (38.8%) denied use or had an unknown history of use.
An opioid was administered to 148 patients (98.7%) in the cohort. Two patients who did not receive an opioid were stimulant positive on admission, met inclusion criteria and were successfully extubated, thus they were included in the analysis. The use of a fentanyl infusion, a hydromorphone infusion, or the sequential administration of a fentanyl and hydromorphone infusion were as follows: 57.1% vs 64.4%, P = .47; 14.3% vs 5%, P = .06; and 18.4% vs 19.8%, P = 1.0, respectively. Oxycodone and methadone use in the stimulant-positive compared with the stimulant-negative arm were 6.1% vs 8.9%, P = .75 and 4.1% vs 1%, P = .25, respectively. The median number of IV opioid bolus doses per day of mechanical ventilation was 2.82 (interquartile range [IQR], 0.94-4.99) in the stimulant-positive arm and 3.07 (IQR, 1.5-5.48) in the stimulant-negative arm (P = .36). The primary end point and median daily opioid requirements, expressed as morphine equivalents, are reported in Table 2 . Different pain scales were used during the study period and are not comparable, thus these data were not recorded.
Sedative administration and assessments are reported in Table 2 . Propofol was the most commonly used sedative, followed by benzodiazepines and dexmedetomidine. For patients receiving a benzodiazepine infusion, midazolam infusions were used most commonly (18.4% vs 23.8%, P = .53), followed by lorazepam infusions (6.1% vs 10.9%, P = .55) or the sequential use of a midazolam and lorazepam infusion (4.1% vs 5.9%, P = 1.0).
To further characterize the medication requirements for these patients, administration of adjunctive sedative and analgesic medications was also collected (Table 3) . For all 9 patients who received ketamine, ketamine was initiated in the setting of multimodal analgesia for uncontrolled pain despite traditional IV opioid therapy and was initiated between days 1 and 3 of intubation. lidocaine transdermal patches placed, 8 received acetaminophen, 3 received nonsteroidal anti-inflammatory drugs, 4 received adjuncts for neuropathic pain, and 2 patients had epidural analgesia. One patient in the stimulant-positive arm had documentation that ketamine was initiated specifically because of a history of polysubstance abuse. The number of visits to the operating room during mechanical ventilation was a median of 1 in each group. Clinical outcomes including the duration of mechanical ventilation, ICU length of stay, hospital length of stay, and in-hospital mortality are reported in Table 4 . Self-extubation was reported for 1 patient in each arm (2.04% vs 0.99%, P = .55), and extubation requiring reintubation within the following 24 hours was not different between groups (6.12% vs 5.94%, P = 1.0). The proportion of patients who received a tracheostomy and the time to tracheostomy were 22.5% vs 27.7%, P = .55 and 5.33 vs 6.84 days, P = .46, respectively. Two patients (18.1%) in the stimulant-positive arm and 6 patients (21.4%) in the stimulant-negative arm received an early tracheostomy (day 2 or 3) because of facial fractures or spinal cord injury. The median Injury Severity Score for patients who received a tracheostomy was 25 (IQR, 22-34) vs 24.5 (IQR, 14.8-37.3, P = .46), and the majority presented with TBI (72.7% vs 57.1%, P = .47), with a median Glasgow Coma Scale score in each group of 7.
Predictors of opioid requirements, defined as greater than the median of 1.24 mg/kg/day of morphine equivalents, were evaluated using a multivariate logistic regression analysis with backward variable selection. In the final model, increasing age and AIS (head and neck) were associated with decreased daily opioid requirements: OR, 0.95 (95% CI, 0.93-0.97) and OR, 0.71 (95% CI, 0.58-0.87), respectively, and preinjury stimulant use was not predictive of opioid requirements (OR, 0.88, 95% CI, 0.40-1.90).
In a second multivariate analysis of a propensity score--adjusted model, the same predictors as those used in the above logistic regression were used to first predict stimulant use. The predicted scores from this model were then used to adjust the stimulant use and predict opioid requirements. In this propensity score--adjusted model, opioid requirements were not significantly affected by preinjury stimulant use (OR, 0.97, 95% CI, 0.44-2.11). In a third logistic model adjusted by quintiles of propensity scores, stimulant use was not a significant predictor of opioid requirements (OR, 0.89, 95% CI, 0.41-1.94).
A post hoc analysis of patients presenting with TBI was performed to determine additional factors influencing the primary and secondary outcomes of the cohort. Baseline characteristics and opioid and propofol requirements in this subgroup are reported in Table 5 .
DISCUSSION
Unexpectedly, the results of this study demonstrate that mechanically ventilated patients with a positive UDS for cocaine and/or amphetamines have widely variable daily opioid or sedative requirements that may not be different from patients with a negative UDS for these agents, when normalized for body weight. Cointoxication with alcohol and cannabinoids was common in this cohort, although it did not appear to affect requirements. Depth of sedation and clinical outcomes did not differ between groups. Stimulant-positive patients presenting with a TBI spent less time within the target RASS range and may have required intervention for elevated intracranial pressure more often, suggesting a more complicated neurological course.
Data examining the effect of drug use disorders and analgesic and sedative requirements during mechanical ventilation in the trauma or surgical patient populations are limited. De Wit et al 9 retrospectively examined sedative requirements in mechanically ventilated medical patients (n = 70) with a history of general substance use, including alcohol (31%), cocaine (7%), and other drugs within the past year, as identified by Diagnostic and Statistical Manual of Mental Disorders criteria. These patients with a history of a drug use disorder received more daily morphine equivalents (0.5 vs 0.1 mg/kg/day, P = .03) and lorazepam equivalents (0.5 vs 0.2 mg/kg/day, P = .004), whereas no difference was noted in propofol requirements, depth of sedation, and duration of mechanical ventilation. Not surprisingly, patient demographics in this study by de Wit et al 9 differed from our study population in several respects: they were older, had a history of alcohol or cocaine within the previous year, rather than acute use of cocaine and/or amphetamines, only a small proportion had a history of stimulant use specifically, and benzodiazepine administration was more www.anesthesia-analgesia.org
ANESTHESIA & ANALGESIA common. In addition, the patients in our study received higher quantities of morphine equivalents than patients in this trial, which might be expected for a trauma cohort compared with a medical one; however, the 5-fold difference in opioid requirements was not reproduced in our study. We also did not appreciate any differences in the administration of adjunctive analgesics or sedative requirements.
Importantly, this study does not distinguish between drug users and abusers. Abuse may occur when a patient experiences adverse socioeconomic or health consequences that are related to the use of a substance, and it often leads to dependence and/or addiction. 19 However, this study is likely a more pragmatic approach because the ability to distinguish between the 2 is often not possible in trauma patients on presentation or early in their hospital course. In this study, 2 patients had a stimulant documented as a home medication. This finding may be conservative given that a large portion of trauma patients had unknown or incomplete past medical histories.
Although preinjury binge use of stimulants was less common, chronic stimulant use was documented for nearly one-half of stimulant-positive patients, and nearly 40% of patients had unknown use or they denied illicit substance use despite a positive UDS. Primary symptoms of stimulant withdrawal include agitation, depressed mood, fatigue, and discomfort. Although not observed in this study, it is possible that patients with chronic substance abuse may require higher doses of sedatives to mitigate this withdrawal syndrome. One potential explanation for this lack of difference may be because of the findings revealed in the subgroup analysis of patients with TBI. Although severity of injury scores at presentation and mean RASS were not statistically different, clinically, the stimulant-positive patients with TBI required intervention for elevated ICP more frequently and appeared to be more deeply sedated despite similar medication use. Less sedation may have been needed because of the evolution of the disease process and a more complicated neurologic course for the stimulant-positive patients, and subsequently, this may have influenced the lack of difference in sedation requirements observed in the larger cohort. These statements are made with caution because of the small sample size of the TBI subgroup.
One interesting finding in this study was the trend toward a greater use of ketamine in the stimulant-positive group. Ketamine administration may reduce perioperative opioid requirements and sensitize opioid receptors, thus it offers an attractive adjunctive agent in the trauma and surgical patient population. [20] [21] [22] [23] Although our findings may reflect an institutional practice among the anesthesiology intensivists at our institution, the role of ketamine and other adjunctive analgesics for patients with a history of stimulant use warrants further exploration. This study has several limitations. First, this was a retrospective study that, among other implications, suggests the potential for treatment bias regarding whether a clinician was aware of the drug screen results before drug selection and titration. There is also the potential for differing sedation practices from 2009 to 2013, with consensus guidelines for pain, agitation, and delirium recommending propofol and dexmedetomidine as first-line sedatives, while minimizing benzodiazepine use. 24 Yet, it is unlikely that these guidelines had a large effect on the results because they were only made available at the latter end of the study period. In light of emerging literature, a cultural transition toward targeting lighter levels of sedation may have occurred in the study period; however, this is difficult to characterize retrospectively, and included patients were equally distributed over time, so we expect that patients were sedated similarly. Drug shortages may have also affected the drug selection during this time period. For example, dexmedetomidine may have been used during a propofol shortage. Finally, registry data from 2006 to 2010 at our institution indicate that approximately 30% of patients receive a UDS at the time of admission after traumatic injury, and that women and patients ≥45 years of age are less likely to receive a UDS. 25 Although similar to previously published reports, 26 this biased screening process may have limited our sample size.
As a strength of its design, this study included patients in the stimulant-positive group based on positive results for cocaine and/or amphetamines and into the stimulantnegative group based on negative results for these agents, regardless of other positive results. Therefore, cointoxications were common in this study. Although this could have altered results, it is likely encountered in practice because cointoxication is common in this patient population. 27 This study is a realistic representation of sedation practice in this patient population over a period of time and offers us guidance on optimal sedation management of these patients.
In summary, achieving desirable pain control and depth of sedation may not require higher doses of analgesic and sedative medications for trauma patients presenting with acute intoxication of cocaine and/or amphetamines compared with their stimulant-negative counterparts. These findings should be interpreted cautiously in light of the wide CI observed in the propensity score-adjusted model. The findings, although unexpected, indicate that empirically increasing analgesic and sedative doses based on positive UDS results for these stimulants may not be necessary. Using a multimodal approach in the management of pain and agitation in this patient population, particularly in the role of ketamine, warrants further exploration. E
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